MARKET

BGNE

BGNE

BeiGene
NASDAQ

Real-time Quotes | Nasdaq Last Sale

300.31
+5.48
+1.86%
After Hours: 300.31 0 0.00% 16:35 04/13 EDT
OPEN
298.73
PREV CLOSE
294.83
HIGH
307.05
LOW
294.12
VOLUME
199.03K
TURNOVER
--
52 WEEK HIGH
388.97
52 WEEK LOW
136.48
MARKET CAP
27.54B
P/E (TTM)
-15.7469
1D
5D
1M
3M
1Y
5Y
BeiGene reaches primary endpoint in late-stage lung cancer trial
Announcing interim late-stage data at the ongoing AACR Annual Meeting 2021, BeiGene (BGNE) says that its anti-PD-1 antibody tislelizumab achieved the primary endpoint in the trial as second- or third-line
Seekingalpha · 1d ago
BeiGene Says Presents Interim Analysis Results Of RATIONALE 303 Trial Of Tislelizumab In Second- or Third-Line Non-Small Cell Lung Cancer At AACR Annual Meeting 2021; Says Global Phase 3 Trial Achieved Primary Endpoint
BeiGene Presents Interim Analysis Results of RATIONALE 303 Trial of Tislelizumab in Second- or Third-Line Non-Small Cell Lung Cancer at the AACR Annual Meeting 2021 The global Phase 3 trial achieved its primary
Benzinga · 1d ago
BeiGene Reports Phase 1b Data For Sitravatinib And Tislelizumab Combination
Commercial-stage biotechnology company BeiGene Ltd. reported data on the combination of tislelizumab and sitravatinib, which is being evaluated for the treatment of so...
TipRanks.com · 1d ago
BeiGene's tislelizumab combo study shows antitumor activity in solid tumors
BeiGene (BGNE) presents clinical data on tislelizumab, in combination with sitravatinib being jointly developed with Mirati Therapeutics (MRTX) at the American Association for Cancer Research ((AACR)) Annual Meeting 2021.Data presented
Seekingalpha · 2d ago
BeiGene Announced Clinical Data on Sitravatinib in Combination with Tislelizumab Showed Preliminary Antitumor Activity in Patients With Unresectable or Metastatic Melanoma Refractory or Resistant to Pd-1/l1 Inhibitors and Platinum-resistant Ovarian Cancer at AACR 2021
BeiGene, Ltd. (NASDAQ: BGNE) today announced that clinical data on its anti-PD-1 antibody tislelizumab, in combination with the investigational spectrum-selective kinase inhibitor sitravatinib being jointly developed with Mirati Therapeutics, Inc.
Benzinga · 2d ago
BeiGene Presents Clinical Data on Sitravatinib in Combination with Tislelizumab at the AACR Annual Meeting 2021
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide,...
BusinessWire - BZX · 2d ago
The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight
Contrary to the strength in the broader market, biotech stocks ended the week ending April 9 lower. The weakness partly reflected a preference for risky bets at the expense of defensives such as healthcare stocks.
Benzinga · 3d ago
Seeking Alpha Catalyst Watch
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a
Seekingalpha · 4d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BGNE. Analyze the recent business situations of BeiGene through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 18 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BGNE stock price target is 346.22 with a high estimate of 509.20 and a low estimate of 170.18.
EPS
Institutional Holdings
Institutions: 334
Institutional Holdings: 57.59M
% Owned: 62.80%
Shares Outstanding: 91.70M
TypeInstitutionsShares
Increased
79
4.51M
New
53
685.75K
Decreased
85
4.78M
Sold Out
48
852.99K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.86%
Pharmaceuticals & Medical Research
+0.68%
Key Executives
Chairman/Chief Executive Officer/Co-Founder/Executive Director
John Oyler
President/Chief Operating Officer/General Manager
Xiaobin Wu
Co-Founder/Non-Executive Director
Xiaodong Wang
Other
Eric Hedrick
Chief Financial Officer
Howard Liang
Other
Jane Huang
Secretary
Hing Ling Chau
Non-Executive Director
Anthony Hooper
Non-Executive Independent Director
Timothy Chen
Non-Executive Independent Director
Donald Glazer
Non-Executive Independent Director
Michael Goller
Non-Executive Independent Director
Ranjeev Krishana
Non-Executive Independent Director
Thomas Malley
Non-Executive Independent Director
Corazon Sanders
Non-Executive Independent Director
Jing-Shyh Su
Non-Executive Independent Director
Qingqing YI
Non-Executive Independent Director
Qingqing Yi
No Data
About BGNE
BeiGene, Ltd. is principally engaged in biopharmaceutical business. The Company is mainly engaged in the research and development, production and sales of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company's main products include Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317) and Pamiparib (BGB-290).

Webull offers kinds of Beigene Ltd (ADR) stock information, including NASDAQ:BGNE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BGNE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BGNE stock methods without spending real money on the virtual paper trading platform.